Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company

    • Home
    • Company
    • Page 581
Company

Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006

Fineline Cube Apr 4, 2007

Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...

Company

China’s Western Pharmaceutical Exports Soar 23% in 2006, Led by Antibiotics

Fineline Cube Apr 4, 2007

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Posts pagination

1 … 580 581

Recent updates

  • Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer
  • Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers
  • Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth
  • Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion
  • Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

Company

Sandoz Forms Global Biosimilars Unit – Metzger-Led Division Targets Accelerated Portfolio Growth

Company Deals

Eli Lilly Commits $3 Billion to China Manufacturing – Orforglipron Production Capacity and Local Supply Chain Expansion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.